O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.29 CNY -3.11% Market Closed
Market Cap: 3.4B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
PP&E Net
ÂĄ1.4B
CAGR 3-Years
174%
CAGR 5-Years
72%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
PP&E Net
ÂĄ26.8B
CAGR 3-Years
22%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
PP&E Net
ÂĄ10.4B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
PP&E Net
ÂĄ30.8B
CAGR 3-Years
20%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
PP&E Net
ÂĄ1.5B
CAGR 3-Years
14%
CAGR 5-Years
34%
CAGR 10-Years
28%
W
WuXi XDC Cayman Inc
HKEX:2268
PP&E Net
ÂĄ1.2B
CAGR 3-Years
60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.4B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.56 CNY
Overvaluation 14%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's PP&E Net?
PP&E Net
1.4B CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's PP&E Net amounts to 1.4B CNY.

What is Obio Technology Shanghai Corp Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
72%

Over the last year, the PP&E Net growth was 76%. The average annual PP&E Net growth rates for Obio Technology Shanghai Corp Ltd have been 174% over the past three years , 72% over the past five years .

Back to Top